Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has received an average recommendation of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $59.44.
Several brokerages recently issued reports on XENE. Citigroup started coverage on Xenon Pharmaceuticals in a report on Thursday, January 4th. They set a “buy” rating and a $62.00 price objective for the company. Bank of America raised their price target on Xenon Pharmaceuticals from $52.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, April 10th. Wedbush raised their price objective on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a research report on Friday, March 1st. Finally, Royal Bank of Canada decreased their target price on shares of Xenon Pharmaceuticals from $56.00 to $55.00 and set an “outperform” rating for the company in a research report on Friday, March 1st.
Check Out Our Latest Research Report on Xenon Pharmaceuticals
Insider Transactions at Xenon Pharmaceuticals
Hedge Funds Weigh In On Xenon Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA grew its position in Xenon Pharmaceuticals by 1,567.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,334 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 1,254 shares during the last quarter. US Bancorp DE increased its position in shares of Xenon Pharmaceuticals by 260.2% during the fourth quarter. US Bancorp DE now owns 933 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 674 shares during the period. Wells Fargo & Company MN lifted its position in Xenon Pharmaceuticals by 124.6% in the fourth quarter. Wells Fargo & Company MN now owns 1,123 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 623 shares during the period. Tower Research Capital LLC TRC increased its holdings in Xenon Pharmaceuticals by 414.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 817 shares during the period. Finally, Parallel Advisors LLC increased its holdings in Xenon Pharmaceuticals by 51.2% in the 4th quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 381 shares during the period. Institutional investors own 95.45% of the company’s stock.
Xenon Pharmaceuticals Trading Down 3.2 %
Shares of NASDAQ XENE opened at $40.31 on Tuesday. The firm has a market capitalization of $3.04 billion, a PE ratio of -14.82 and a beta of 1.15. Xenon Pharmaceuticals has a one year low of $27.99 and a one year high of $50.99. The business has a 50-day moving average price of $45.00 and a two-hundred day moving average price of $40.80.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.12. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) earnings per share. Research analysts anticipate that Xenon Pharmaceuticals will post -3.04 EPS for the current year.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Further Reading
- Five stocks we like better than Xenon Pharmaceuticals
- What is the Hang Seng index?
- Comprehensive PepsiCo Stock Analysis
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- About the Markup Calculator
- Bear Market Funds to Watch This Year
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.